Top Page
ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H
(1541)
ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H (1541) vs. iShares MSCI Hong Kong ETF (EWH)
ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H Business Overview & Revenue Model
ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H Financial Statement Overview
| Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|
Income Statement | ||||
| Total Revenue | 74.15M | 386.00K | 538.00K | 5.07M |
| Gross Profit | 74.15M | 424.65K | 538.00K | 5.07M |
| EBITDA | -295.63M | -355.35M | -384.49M | -718.88M |
| Net Income | -315.86M | -379.46M | -402.89M | -732.95M |
Balance Sheet | ||||
| Total Assets | 922.00M | 874.59M | 839.98M | 892.84M |
| Cash, Cash Equivalents and Short-Term Investments | 752.12M | 608.56M | 635.21M | 668.33M |
| Total Debt | 136.36M | 74.77M | 14.62M | 18.54M |
| Total Liabilities | 243.69M | 126.30M | 60.76M | 2.49B |
| Stockholders Equity | 678.90M | 748.29M | 779.22M | -1.60B |
Cash Flow | ||||
| Free Cash Flow | -138.44M | -370.25M | -261.93M | -315.79M |
| Operating Cash Flow | -128.03M | -367.55M | -238.71M | -190.54M |
| Investing Cash Flow | 37.95M | -294.85M | 49.00K | -108.72M |
| Financing Cash Flow | 258.93M | 331.04M | 179.38M | 793.03M |
ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H Technical Analysis
ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
62 Neutral | HK$8.39B | 229.14 | 4.16% | ― | 34.39% | ― | |
57 Neutral | HK$8.59B | ― | -13.97% | ― | -97.81% | -117.20% | |
55 Neutral | HK$7.19B | ― | -22.23% | ― | -14.17% | 76.00% | |
55 Neutral | €4.64B | 17.01 | -50.16% | 3.66% | 15.32% | -9.52% | |
51 Neutral | HK$8.84B | ― | -51.40% | ― | 58.75% | -1310.16% | |
46 Neutral | HK$7.94B | ― | -44.39% | ― | 18989.90% | 18.84% |
ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H Corporate Events
ImmuneOnco Biopharmaceuticals has observed unusual price movements in its shares but confirms that there is no undisclosed information or adverse changes in its business operations and financial position. The company advises shareholders and potential investors to exercise caution when dealing with its shares.
ImmuneOnco Biopharmaceuticals has announced that its partner, Instil Bio, has received IND clearance from the U.S. FDA for IMM2510/AXN-2510, a bispecific antibody for solid tumors. This development paves the way for a Phase 1b/2 trial in the U.S. by the end of 2025, potentially enhancing the company’s market position in cancer therapies.
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. has established a Nomination Committee to improve its corporate governance structure. This committee is responsible for the selection and appointment of directors and senior management, aiming to optimize board composition and enhance decision-making processes.
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. has announced the composition of its board of directors and their roles within the company. This announcement outlines the executive, non-executive, and independent non-executive directors, as well as their assignments to various board committees, which are crucial for the company’s governance and strategic decision-making processes.
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. announced changes to its Nomination Committee, appointing Ms. Fu Dawei and Dr. Kendall Arthur Smith as new members. These changes align with upcoming amendments to the Hong Kong Stock Exchange’s Listing Rules and Corporate Governance Code, aiming to enhance the company’s governance practices and board diversity.
ImmuneOnco Biopharmaceuticals has received approval from the National Medical Products Administration of China to initiate a clinical trial for IMC-003/IMM72, a treatment for pulmonary arterial hypertension. This development marks a significant step in the company’s efforts to advance its pipeline of innovative therapies, potentially enhancing its position in the biopharmaceutical industry.
ImmuneOnco Biopharmaceuticals announced the redemption of HK$200,000,000 from a wealth management product with Haitong ASM, resulting in an estimated gain of HK$5,102,000. The company also subscribed to a new wealth management product with Shenwan Hongyuan Securities for HK$205,000,000, funded by its internal surplus cash reserves. These transactions are part of the company’s strategy to optimize returns on idle funds and align with its treasury policy, enhancing overall financial flexibility and returns.
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. has announced the appointment of Dr. Wu Zhuli as the new Chief Medical Officer, effective June 9, 2025. Dr. Wu brings over 13 years of experience in clinical drug development, having previously worked at leading pharmaceutical companies such as Janssen Pharmaceuticals, Roche, and Fosun Pharma. Her leadership at Fosun Pharma led to significant achievements, including the approval of numerous investigational new drug applications and the market launch of Luvometinib, a groundbreaking treatment for histiocytic tumors and pediatric neurofibroma. This strategic appointment is expected to enhance the company’s clinical development capabilities and strengthen its position in the biopharmaceutical industry.
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. held its Annual General Meeting on May 28, 2025, where all proposed resolutions were approved by shareholders. The meeting saw the appointment of Mr. Zhang Ruliang as an executive director and Ms. Fu Dawei as a non-executive director, along with the re-election of Dr. Tian Wenzhi as an executive director. These decisions are expected to strengthen the company’s leadership and potentially enhance its strategic direction in the biopharmaceutical industry.
ImmuneOnco Biopharmaceuticals has announced the composition of its board of directors and their roles within the company. This announcement outlines the structure of the board, including executive, non-executive, and independent non-executive directors, as well as the composition of various board committees, which could impact the company’s governance and strategic direction.
ImmuneOnco Biopharmaceuticals announced a supplemental disclosure regarding its subscription of wealth management products. The company extended its 2023 Subscription and initiated a 2024 Subscription using internal surplus cash reserves. Initially considered immaterial, these transactions were later recognized as discloseable under Chapter 14 of the Listing Rules due to the percentage ratios involved. The company acknowledged its oversight in compliance and has implemented corrective measures to enhance internal controls and training on the Listing Rules.
ImmuneOnco Biopharmaceuticals has announced updates on its clinical trials for IMM2510/AXN-2510, a PD-L1 and VEGF bispecific antibody, in combination with chemotherapy for first-line treatment of non-small cell lung cancer (NSCLC) in China. The Phase 2 trial is expected to complete enrollment by the third quarter of 2025, with initial safety and efficacy results anticipated in the second half of 2025. The company plans to initiate a Phase 3 trial in mid-2026, subject to regulatory discussions. The announcement highlights the potential of IMM2510/AXN-2510 to improve treatment outcomes in NSCLC, positioning ImmuneOnco as a competitive player in the oncology field.
ImmuneOnco Biopharmaceuticals has successfully completed the conversion of 14,114,006 Unlisted Shares into H Shares, with the listing of these shares commencing on May 15, 2025. This move increases the proportion of H Shares in the company’s capital structure to 97.29%, potentially enhancing liquidity and investor interest in the company’s stock.
ImmuneOnco Biopharmaceuticals has received a second payment of $5 million from Axion Bio as part of their license and collaboration agreement, totaling $20 million received so far. This milestone strengthens their collaboration and supports further advancements in their cancer-targeting therapies, with potential future payments of up to $30 million anticipated.
ImmuneOnco Biopharmaceuticals has announced the appointment of Dr. Weihai He as the new Chief Business Officer, effective May 5, 2025. Dr. He brings extensive experience in business development and strategic marketing from her previous roles at prominent organizations such as the Bill & Melinda Gates Foundation and Merck KGaA. Her appointment is expected to strengthen ImmuneOnco’s business operations and enhance its strategic positioning in the biopharmaceutical industry.
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. has announced its upcoming Annual General Meeting scheduled for May 28, 2025. The meeting will address several key resolutions, including the approval of the 2024 work reports, financial reports, and profit distribution plan. Additionally, the company will consider the appointment and re-election of various directors and supervisors, as well as the re-appointment of Deloitte Touche Tohmatsu as the auditor for 2025. A special resolution will also be discussed regarding the granting of a general mandate to the Board for issuing new shares.
ImmuneOnco Biopharmaceuticals has received approval from the Hong Kong Stock Exchange for the listing and trading of 14,114,006 converted H shares, as part of its participation in the H share full circulation program. This approval marks a significant step in the company’s efforts to enhance its market presence and liquidity, with the converted shares representing approximately 3.56% of the total issued H shares.